JPMorgan: Merck/Daiichi Sankyo Withdrawal of B7-H3 ADC Filing Is a Positive for Hansoh Pharma/GSK's Ris-Rez

Stock News
Sep 28

JPMorgan has issued a research report maintaining its "Overweight" rating on Hansoh Pharma (03692) with a target price of HK$50.

Merck (MRK.US) and Daiichi Sankyo (4568.JP) have voluntarily withdrawn the U.S. Biologics License Application (BLA) for their B7-H3 ADC drug ifinatamab deruxtecan (I-DXd) for previously treated extensive-stage small cell lung cancer (ES-SCLC). From a competitive timeline perspective, this represents an incremental positive for Hansoh Pharma/GSK's Ris-Rez.

The report notes that prior to the withdrawal, I-DXd's BLA had received priority review, with an original FDA PDUFA date of October 10, 2026. Future U.S. submission now depends on the ongoing Phase III IDeate-Lung02 study, which may complete enrollment in the coming months. Clinical trial registrations indicate a completion date around early 2028, meaning a new BLA could be submitted in early 2028.

This event weakens I-DXd's U.S. first-mover advantage and shifts focus more toward randomized Phase III overall survival (OS) and safety evidence. The bank believes that Ris-Rez has already reported positive OS data from the randomized Phase III ARTEMIS-008 trial in China and is being evaluated in GSK's global Phase III EMBOLD SCLC-301, with data readouts potentially in 2027/2028 and a potential U.S. submission falling around 2028, similar in timing to I-DXd's new submission.

According to WCLC'26 data, Ris-Rez demonstrated a median OS of 18.5 months versus 10.3 months for Topotecan in second-line and beyond ES-SCLC, with a hazard ratio of 0.46; median progression-free survival of 7.2 months versus 3 months; and an objective response rate of 58.3% versus 12.6%.

The bank notes that Ris-Rez's efficacy data appears to lead I-DXd's Phase II results, but differences in trial design and patient populations make direct head-to-head comparison inappropriate. Regarding safety, Ris-Rez showed a treatment-related interstitial lung disease incidence of 11.7% with no Grade 4/5 events, compared to 12.4% for I-DXd in Phase II, which included Grade >3 events.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10